


Western blots

Figure 1A


- p21 and Actin IMR90 cells 6n



C: control

D: doxorubicin 250 nM, 24 h.

- P53 and Actin IMR90 cells 6n




C: control

D: doxorubicin 250 nM, 24 h.

Figure 1C

- Bcl-xL and Actin IMR90 cells 6n




C: control


D: doxorubicin 250 nM, 24 h.

Figure 1E

- p21 and Actin IMR90 cells 6n



- Bcl-xl and Actin IMR90 cells 3-4n




C: control


E: etoposide 40 μ M, 24 h.

Figure 1H

- p21 and Actin IMR90 cells 6n



- Bcl-xL and Actin A549 cells 4n




C: control

D: doxorubicin 250 nM, 24 h.

E: etoposide 40 μ M, 24 h.

Figure 4C

- PARP1 and Actin IMR90 cells 3n



C: control

D: doxorubicin 250 nM, 24 h.


A: ABT 3 μ M.

D+A: doxorubicin 250 nM+ ABT 3 μ M.

C1: senescent 12 days post doxo 250 nM + ABT 2.5 μ M

C2: senescent 12 days post doxo 250 nM + ABT 5 μ M

Figure 5E



TCEt





Figure S2

- Micu1 and Actin IMR90 cells 3n




C: control

D: doxorubicin 250 nM, 24 h.

A: ABT 3 μ M.

D+A: doxorubicin 250 nM+ ABT 3 μ M.

- MCU and Actin IMR90 cells 5n




C: control

D: doxorubicin 250 nM, 24 h.

A: ABT 3 μ M.

D+A: doxorubicin 250 nM+ ABT 3 μ M.


- VDAC1 and Actin IMR90 cells 6n




C: control

D: doxorubicin 250 nM, 24 h.


- IP3R1



- IP3R2



- IP3R3




- HSP90




Figure S3

MICU1 Dox abt




- 45 kDa (β -actin)



- 31 kDa (MICU1)

MCU Dox abt




- 45 kDa (β -actin)



- 40 kDa (MCU)

VDAC1 Dox abt




- 45 kDa (β -actin)




- 32 kDa (VDAC1)

IP3R1 Dox abt



- 314 kDa (IP3R-I)




- 90 kDa (HSP90)

IP3R2 Dox abt



- 300 kDa (IP3R-II)



- 90 kDa (HSP90)

IP3R3 Dox abt






Figure S4





- 30 kDa (Bcl-xL)